The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments, smoking history, conditions of initiation of treatment (presence of an EGFR-activating mutation) and to evaluate the impact of treatment on the health of the population concerned in terms of morbidity and mortality (clinical benefit, safety,...) and quality of life
Descriptive pharmacoepidemiological study of patients treated with Iressa
Study Type
OBSERVATIONAL
Enrollment
361
Research Site
Aulnay-sous-Bois, France
Research Site
Bayonne, France
The Overall survival
Time frame: 24 months
The progression free survival
Time frame: 24 months
Description of Quality of life by Functional Assessment of Cancer Therapy - Lung including Life Stressor Checklist (FACT-L including LSC)
Time frame: baseline
Description of Quality of life by Functional Assessment of Cancer Therapy - Lung including Life Stressor Checklist (FACT-L including LSC)
Time frame: From baseline to 3 months
Description of Quality of life by Life Stressor Checklist - Lung (LSC-L)
Time frame: From 3 months to 6 months
Description of Quality of life by Life Stressor Checklist - Lung (LSC-L)
Time frame: From 6 months to 12 months
Description of Quality of life by Life Stressor Checklist - Lung (LSC-L)
Time frame: From 12 months to 18 months
Description of Quality of life by Life Stressor Checklist - Lung (LSC-L)
Time frame: From 18 months to 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Bordeaux, France
Research Site
Bron, France
Research Site
Carcassonne, France
Research Site
Chalon-sur-Saône, France
Research Site
Cholet, France
Research Site
Clamart, France
Research Site
Colmar, France
Research Site
Corbeil-Essonnes, France
...and 19 more locations